Precision BioSciences Announces Late-Breaking Preclinical Data for PBGENE-DMD Gene Editing Therapy; IND Filing Expected by End of 2025

Reuters

Sep 30, 2025

Precision BioSciences Announces Late-Breaking Preclinical Data for PBGENE-DMD Gene Editing Therapy; IND Filing Expected by End of 2025

Precision BioSciences Inc. has announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society $(WMS)$, scheduled for October 7-12, 2025, in Vienna, Austria. The company will present new preclinical data for its investigational gene editing therapy, PBGENE-DMD, which is being developed for the treatment of Duchenne muscular dystrophy (DMD). According to Precision BioSciences, PBGENE-DMD is designed to address dystrophin mutations between exons 45-55 and may benefit up to 60% of patients with DMD. The company anticipates filing an investigational new drug (IND) and/or clinical trial application $(CTA)$ by the end of 2025, with initial clinical data expected in 2026. The results of the preclinical studies will be presented at the upcoming WMS congress and have not yet been publicly disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250930417047) on September 30, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571834940"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571834940\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571834940?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571834940","market":"nz","top_or_hot":-1,"title":"Precision BioSciences Announces Late-Breaking Preclinical Data for PBGENE-DMD Gene Editing Therapy; IND Filing Expected by End of 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Precision BioSciences Announces Late-Breaking Preclinical Data for PBGENE-DMD Gene Editing Therapy; IND Filing Expected by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Precision BioSciences Inc. has announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society <a href=\"https://laohu8.com/S/WMS\">$(WMS)$</a>, scheduled for October 7-12, 2025, in Vienna, Austria. The company will present new preclinical data for its investigational gene editing therapy, PBGENE-DMD, which is being developed for the treatment of Duchenne muscular dystrophy (DMD). According to Precision BioSciences, PBGENE-DMD is designed to address dystrophin mutations between exons 45-55 and may benefit up to 60% of patients with DMD. The company anticipates filing an investigational new drug (IND) and/or clinical trial application <a href=\"https://laohu8.com/S/CTA\">$(CTA)$</a> by the end of 2025, with initial clinical data expected in 2026. The results of the preclinical studies will be presented at the upcoming WMS congress and have not yet been publicly disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250930417047) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precision BioSciences Announces Late-Breaking Preclinical Data for PBGENE-DMD Gene Editing Therapy; IND Filing Expected by End of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecision BioSciences Announces Late-Breaking Preclinical Data for PBGENE-DMD Gene Editing Therapy; IND Filing Expected by End of 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Precision BioSciences Announces Late-Breaking Preclinical Data for PBGENE-DMD Gene Editing Therapy; IND Filing Expected by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Precision BioSciences Inc. has announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society <a href=\"https://laohu8.com/S/WMS\">$(WMS)$</a>, scheduled for October 7-12, 2025, in Vienna, Austria. The company will present new preclinical data for its investigational gene editing therapy, PBGENE-DMD, which is being developed for the treatment of Duchenne muscular dystrophy (DMD). According to Precision BioSciences, PBGENE-DMD is designed to address dystrophin mutations between exons 45-55 and may benefit up to 60% of patients with DMD. The company anticipates filing an investigational new drug (IND) and/or clinical trial application <a href=\"https://laohu8.com/S/CTA\">$(CTA)$</a> by the end of 2025, with initial clinical data expected in 2026. The results of the preclinical studies will be presented at the upcoming WMS congress and have not yet been publicly disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250930417047) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DTIL","symbol_name":"Precision Biosciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDLzZtpf:1","article_id":"2571834940","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571834940","pubTimestamp":1759230081,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Precision BioSciences Announces Late-Breaking Preclinical Data for PBGENE-DMD Gene Editing Therapy; IND Filing Expected by End of 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire  on September 30, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DTIL":"Precision Biosciences Inc","BK4139":"生物科技"},"translate_title":"Precision BioSciences公布PBGENE-DMD基因编辑疗法的最新临床前数据；预计2025年底提交IND","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DTIL":0.9},"content_text":"Precision BioSciences Announces Late-Breaking Preclinical Data for PBGENE-DMD Gene Editing Therapy; IND Filing Expected by End of 2025\n    \n\n        Precision BioSciences Inc. has announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society $(WMS)$, scheduled for October 7-12, 2025, in Vienna, Austria. The company will present new preclinical data for its investigational gene editing therapy, PBGENE-DMD, which is being developed for the treatment of Duchenne muscular dystrophy (DMD). According to Precision BioSciences, PBGENE-DMD is designed to address dystrophin mutations between exons 45-55 and may benefit up to 60% of patients with DMD. The company anticipates filing an investigational new drug (IND) and/or clinical trial application $(CTA)$ by the end of 2025, with initial clinical data expected in 2026. The results of the preclinical studies will be presented at the upcoming WMS congress and have not yet been publicly disclosed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250930417047) on September 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}